26 results
6-K
EX-99.1
GMDAQ
Gamida Cell Ltd
21 Feb 19
Current report (foreign)
2:06pm
aplastic anemia, which supports further exploring a reduced intensity regimen and highlights the potential of NiCord as a bone marrow transplant solution … with reduced intensity conditioning regimens and underwent a bone marrow transplant consisting of NiCord plus a haploidentical stem cell graft
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
27 Sep 23
Regulation FD Disclosure
4:43pm
and intensity of infusion reactions. In patients transplanted with OMISIRGE in clinical trials, 47% (55/117) patients had an infusion reaction of any
6-K
EX-99.2
GMDAQ
Gamida Cell Ltd
9 Dec 20
Report of Foreign Private Issuer
3:37pm
- anemia. Clinicaltrials.gov identifier NCT03173937. Patients with severe aplastic anemia (N = 3) Reduced - intensity conditioning Omidubicel … + haploidentical stem cells Patients with severe aplastic anemia (N = 6) Reduced - intensity conditioning Omidubicel Cohort 1 Cohort 2 Samour et al ASH 2020
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
. Premedication with antipyretics, histamine antagonists, and corticosteroids may reduce the incidence and intensity of infusion reactions. In patients
6-K
EX-99.1
GMDAQ
Gamida Cell Ltd
9 Mar 21
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
4:08pm
and robust immune reconstitution following reduced intensity conditioning. The data suggest that omidubicel can result in rapid engraftment and can achieve
10-Q
ovi20k4jc vp8a3
12 May 22
Quarterly report
7:42am
F-1/A
4g6xw
26 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1
56nvofuh9 v2f
24 Jun 19
Registration statement (foreign)
4:04pm
424B4
vl0nj i02veflf
28 Jun 19
Prospectus supplement with pricing info
3:51pm
20-F
rtkuz
25 Feb 19
Annual report (foreign)
5:08pm
10-K
bkep07mo 0vuou0ei
24 Mar 22
Annual report
7:30am
DRS
mlvjhdlh7ac8
1 Jun 18
Draft registration statement
12:00am